AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M

AN2 Therapeutics, Inc.

2022-Q3 EPS reported -$2.21

Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.
R&D expenses increased vs. Q3 2021 due to license fee, clinical activity, and personnel costs.
Enrollment ongoing in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; Phase 2 top-line data expected ~9 months after enrollment completion.
Awarded up to $17.8M NIAID contract to develop epetraborole for acute systemic melioidosis.
Phase 1 study in Japanese subjects supports 500mg once-daily dose regardless of ADH genotype.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AN2 Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

AN2 Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.